Higgins Jack 4
4 · Immunome Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Immunome (IMNM) CSO Jack Higgins Gifts 6,291 Shares
What Happened
Jack Higgins, Chief Scientific Officer of Immunome Inc. (IMNM), reported a gift of 6,291 common shares on 2026-03-30. The Form 4 lists the transaction as a gift (transaction code G) with a reported price of $0.00 and total value $0. The filing notes these shares are held in a custodial account for his child under the Uniform Transfer to Minors Act and that Higgins disclaims beneficial ownership.
Key Details
- Transaction date: 2026-03-30 (reported on Form 4 filed 2026-04-01) — filed within the standard two-business-day window.
- Transaction type/code: Gift (G); price shown $0.00; shares disposed: 6,291.
- Shares owned after transaction: Not specified in this filing.
- Footnote: Shares held in a custodial UTMA account for his child; Reporting Person disclaims beneficial ownership. Shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025.
- Filing timeliness: Timely (no late filing indicated).
Context
Gifts are transfers of ownership and do not represent a cash sale or a direct market sentiment signal. Because these shares are held in a custodial account and the reporting person disclaims beneficial ownership, the transfer likely reflects a personal/familial transfer rather than an investment decision by the insider.
Insider Transaction Report
- Gift
Common Stock
2026-03-30−6,291→ 31,438 total
- 1,000(indirect: By Children)
Common Stock
[F1] - 1,000(indirect: By Children)
Common Stock
[F1] - 1,000(indirect: By Children)
Common Stock
[F1]
Footnotes (1)
- [F1]The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025.